© 2021 MJH Life Sciences and Cure Today. All rights reserved.
© 2021 MJH Life Sciences™ and Cure Today. All rights reserved.
May 07, 2021
Interim results from a phase 2 study demonstrated that patients inoperable or advanced intrahepatic cholangiocarcoma and a FGFR2 gene mutation had a disease control rate of 79% when treated with derazantinib.
Patients with melanoma treated with Keytruda had improved recurrence-free survival without an effect on their quality of life.
May 06, 2021
Compared to a hypomethylating agent alone, combining the agent with Venclexta improved complete remission rates in patients with blast-phase myeloproliferative neoplasm.
Virtual visits during the COVID-19 pandemic improved satisfaction and convenience, as well as reduced stress and anxiety in veterans who have survived cancer.
How Can Cancer Survivors Help The Newly Diagnosed?
CURE Honors World Ovarian Cancer Day
Derazantinib May Demonstrate Promising Disease Control in Some Patients With Cholangiocarcinoma
You May Have Second Thoughts When Receiving a Cancer Diagnosis